EDN1 and Obesity: Similar to changes typically present in animal models of obesity [12], [13], [22] and obese humans [23]–[26], the GPER0 obesity model is characterized by visceral obesity [18], [19], [27], dyslipidemia [27], insulin resistance [27] as well as enhanced responses to endothelium-derived vasoconstrictor prostanoids and to endothelin-1 [14], [28].